TOKYO–(Business Phone)–Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, later “Elix”) and SEEDSUPPLY Inc. (CEO: Naoki Tarui / HQ: Kanagawa, hereafter “SEEDSUPPLY”) announced the start of joint research.
SEEDSUPPLY (https://www.seedsupply.co.jp/) proposes an efficient drug discovery process for small molecules that uses bond selection technology as a screening method for the lead compound. This technology can probe proteins or RNA, thus providing a drug discovery seed for a variety of therapeutic targets, including those for which biological activity measurement is difficult. In addition, a restricted compound database designed for specific drug exposure target classes is used for target selection, improving the efficiency and success rate of drug discovery methods. In addition, the database shows potential for wider application.
Elix (https://www.elix-inc.com/) is an AI drug discovery company with a mission of “Inventory Insights.” To reduce cost and time while increasing the success rate of the drug discovery pipeline, Elix is focusing on using machine learning in projects aimed at pharmaceutical companies, universities and research institutions. Elix has developed and released “Elix Discovery™,” the all-in-one platform for AI drug discovery, which provides everything from models for material prediction and molecular design, to and support implementation in a single package (https: //www.elix -inc.com/news/newsrelease/1620/). In addition to providing current drug research support, Elix is also considering domestic drug discovery in the future.
In this joint research project, SEEDSUPPLY will use Elix’s AI technology with the goal of making inspections more efficient. Elix integrates SEEDSUPPLY’s data assets, particularly its data on drug discovery targets such as membrane proteins, into an AI training pipeline, thereby advancing the technology for in silico techniques to screen for compounds with improved efficacy.
Elix and SEEDSUPPLY aim to use their unique strengths to reduce the cost and time of cheap drug discovery and to achieve targets that have proven difficult for drug discovery approaches.
Comment by Elix CEO Shinya Yuki
By combining the data obtained from SEEDSUPPLY’s proprietary technology with our proprietary AI models, we hope to discover more unique technological developments. We believe that this technology can make a significant contribution to the investigation of the most difficult targets at a low cost in short periods of time, and to efficiently search a wide range of chemical fields.
A message from SEEDSUPPLY CEO Naoki Tarui
Our company’s bond set database is of high quality, as everything is measured using the same method. Combined with Elix’s superior AI technology, we hope to create new developments in AI drug discovery technology.